The objective of the study was to identify the relationship between gestational weight gain, type of treatment used, and the weight of the baby at birth. This being an observational retrospective study, the primary outcomes evaluated were: the type of treatment used and the classification of the baby's weight at birth. Collection occurred from January 2013 to May 2015. Multivariate multinomial logistic regression models were used to calculate odds ratios. Of the 682 pregnant women, 393 (57.6%) had a weight gain that was less than adequate, 140 (20.5%) showed adequate weight gain, and 149 (21.9%) had a weight gain that was higher than adequate. Weight gain that was less than adequate did not correlate with treatment used or with birth weight classification; higher-than-adequate weight gain was also not associated with the type of treatment used but decreased the chance of having a child considered normal for its gestational age by 50% and doubled the chance of having child considered large for gestational age. Comparing the groups according to the weight gain by means of the odds ratio, no difference was found in the therapy used.
INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as a glucose intolerance that begins or is first detected during gestation. Like other forms of hyperglycemia, GDM is characterized by insufficiency of beta-pancreatic cells to supply the body's demand for insulin. According to the criteria of the new International Association of the Diabetes and Pregnancy Study Group, a heterogeneous multinational cohort study was conducted with a sample of pregnant mothers of various races in the gestational period between 24-32 weeks. In general, 55% of pregnant women in this study Hyperglycemia and Adverse Pregnancy Outcome presented with fasting blood glucose levels (FBG) at the limit for GDM, 33% presented with the diagnostic value at 1 h, and 12% with the diagnostic value at 2 h 1 . A diagnosis of GDM is always compatible with a clinical treatment, often beginning with proper eating procedures and physical activity programs. However, if these measures are not satisfactory, pharmacological treatment is initiated in concomitance with a dietary program. As for dietary treatment, it must be based on a food program that simultaneously allows for adequate weight gain and congruent metabolic control 2 . However, if the glycemic levels continue to be abnormal after the two-week treatment period, the use of pharmacological drugs should be initiated 3 . The choice of therapy in GDM is of great importance for scientific research, mainly due to complications and perinatal complications, as well as variables that may interfere with the dosages and/or type of treatments. The literature reveals that, in general, treatment for GDM recommends insulin as the main drug to be administered. However, conforming with adjustments and/or associations with human insulin, as well as the benefits of its rapid and intermediate action, is of fundamental importance, since dose adjustment should be individualized for each patient 4 .
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However, recent study has verified the possibility of using oral antihyperglycemic agents, this being a gradually more-accepted option in the outcomes of GDM 5 . On the other hand, it is worth highlighting that studies in the 1990's that contraindicated the use of oral antihyperglycemic agents during pregnancy, due to case reports and small sample studies which suggested adverse effects on fetal development 6 . The ideal weight gain during gestation presented alternating measures in the literature 7 . Scientifically, weight gain should vary according to pre-gestational body mass index (BMI), both for diabetics and for patients without comorbidities.
In the 2000's, a study with pregnant women without GDM concluded a relationship between excessive weight gain during gestation with outcomes of macrosomic fetuses and a greater need for cesarean deliveries. On the other hand, the study revealed that pregnant women who acquired an inadequately low weight gain generated fetuses with low birth weight and higher numbers of preterm deliveries 8 . Thus, the purpose of this study is to identify the relationship between gestational weight gain and outcomes in GDM, type of treatment used, and the baby's weight at brith.
METHODS
We performed a retrospective observational study of data obtained through the analysis of medical records of pregnant women diagnosed with GDM and information collected from their children's records. According to the criteria of the International Association of Diabetes and Pregnancy Study Groups, patients older than 18 years should be diagnosed with GDM based on the alteration of any alteration in blood glucose value (fasting ≥ 92 mg/dL, 1 hour postprandial ≥ 180 mg/dL) 9 . Pregnant women who were included in the study had single pregnancies and newborns without malformations. Pregnant women with incomplete medical records and pregnant women who did not adhere to the nutritional program (according to their report) were excluded.
The collection period occurred between January 2013 and May 2015. The pregnant women were attended at the diabetes outpatient clinic of a public maternity hospital in the south of Brazil, in the city of Joinville, SC. All the pregnant women received explanations about the research in the outpatient clinic and had the opportunity to read the informed consent form (ICF) and freedom to sign and to participate or not in the study. The treatment followed the treatment standards of the hospital and the follow-up was done by medical residents belonging to the research group and by the doctor professor responsible for the unit, who also belongs to the group and coordinates the research.
The research was conducted according to the regulations of Resolution 466/12 of the National Health Council and the Helsinki agreement. The anonymity of the pregnant women and their children has been preserved. The study was approved for implementation through the Brazilian Platform under number CAAE: 48289615.3.0000.5366, and by the Research Ethics Committee number 5366. There is no conflict of interest in this study.
GDM treatment was performed through a macro and micro-alimentary diet, under the supervision of the hospital's nutritional guidance service. Follow-up was performed with fasting blood glucose and 1 hour after the main meals. The calculation of the total caloric value of the diet was done according to the BMI of the pregnant woman 10 . The type and frequency of physical activities were based on the guidelines of the Brazilian Society of Diabetes (daily aerobic activity, preferably in the morning or at least 3 days of the week, not going more than 2 days without exercise, with a duration of 150 minutes/week of moderate intensity exercises) 3 . Gestational age, BMI, and fetal abdominal circumference were also considered in the choice of therapy. Metformin was the treatment of choice when therapy involving the hospital's nutritional program and prescribed physical activity was not sufficient. Similarly, insulin was used after treatment failure with metformin. At late diagnosis (greater than 35 weeks) according to the parameters evaluated, insulin therapy was used without previous administration of metformin. We classify weight gain according to the recommendations put forth in 2009
Association between gestational weight gain, birth weight classification, and type of treatment in diabetic mothers by the Institute of Medicine (IOM), which considers pre-gestational BMI, as follows: for pregnant women with low weight, the recommended gain is 13 to 18 kg; for normalweight pregnant women, the recommended gain is 11 to 16 kg; for overweight pregnant women, the recommended gain is 7 to 11 kg; for obese pregnant women, the recommended gain is 5 to 9 kg. Therefore, an insufficient weight gain was classified as "below adequate" and a high weight gain was classified as "above adequate"
11 . The data collected were: age, gestational age when diagnosed with GDM; pregestational BMI, gestational weight gain, number of pregnancies, fasting blood glucose levels, postprandial blood glucose levels, diet prescription, metformin use, insulin delivery, type of delivery, Apgar in the first and fifth minutes, gestational age of delivery (verified by date of last menstrual period and early ultrasound), baby's weight at birth, number of premature infants (less than 37 weeks), as well as the number of children classified as small for gestational age (SGA) (those below the 10th percentile), adequate for gestational age (AGA) (those between the 10 th and 90 th percentile), large for gestational age (LGA) (those above the 90th percentile), and macrosomic (MCR) (more than 4,000 g).
The data were stored in the Excel ® 2010 program, using the SPSS 21 program for statistical analysis. The nominal variables were analyzed in absolute numbers and percentages; the continuous variables in means and standard deviations. Fisher's exact Q² test was used for analysis of ratios, Kruskal-Wallis for independent samples according to the three groups selected, according to the gestational weight gain, Student's t-test for comparisons of the means between the selected groups was used only for maternal characteristics and type of treatment according to gestational weight gain. Multinomial multivariate logistic regression models were constructed (categorical variables) and, consecutively, the odds ratio was calculated in order to verify if the weight gain of the diabetic pregnant woman interfered with the treatment used and the baby's weight at birth. For these comparisons it is worth mentioning that the groups of pregnant women with above-and below-adequate weight gain were compared to pregnant women with adequate weight gain. Confounding variables were: maternal age, gestational age of the diagnosis, pre-gestational BMI, and type of treatment. 95% confidence intervals (95% CI) were established, and significant values were considered when P < 0.05.
RESULTS
Among the 682 pregnant women, 393 (57.6%) presented below-adequate weight gain, 140 (20.5%) presented adequate weight gain, and 149 (21.8%) presented aboveadequate weight gain.
As far as the general characteristics of the study population, the pregnant women had an average age of 30 years, and 28% of the mothers were primigravidae. The mean pregestational BMI was 29 kg/m² and the mean weight gain during pregnancy was 6.9 kg. Most patients, that is, 291 (42.7%) were obese, and only 5 (0.7%) were underweight. Table 1 shows the maternal characteristics in the three groups selected according to gestational weight gain. The age of the pregnant women and the number of previous pregnancies did not highlight differences regarding the weight gain of the mothers. However, gestational age at the time of diagnosis and pregestational BMI showed significant results (P < 0.01), both in mothers whose weight gain was below-and above-adequate.
Therapeutic measures were proposed for all pregnant women as follows: dietary therapy was used for 282 (41.3%) pregnant women who did not require complementary therapy; treatment with insulin for 102 (14.9%) of the women; metformin was required for 242 (35.4%) of the women; and lastly the combination metformin with insulin for 56 (8.2%) of the pregnant women in the study.
The use of the therapies "diet" and "metformin plus insulin" did not show differences among the three groups selected, indicating a non-significant value (P > 0.05). However, treatments with "insulin" and "metformin", applied separately, showed significant results with P = 0.00 (P < 0.01) Association between gestational weight gain, birth weight classification, and type of treatment in diabetic mothers for both types of intervention according to gestational weight gain categorizations.
After the therapeutic measures were applied, fasting blood glucose levels was 89.4 mg/dL (SD 12 mg/dL) and postprandial glucose was 117 mg/dL (SD 17.5 mg/dL) in pregnant women of adequate weight. In the three groups, the analysis comparing the glycemic levels with the respective treatments administered showed significance in the fasting blood glucose levels (P < 0.01) and consecutively there was no statistical significance regarding the postprandial blood glucose levels (P = 0.26).
In the present study, the most common way of delivery was cesarean section, with 52.5% (358) of the children born by this means; 7.1% (49) of the newborns were premature. As for Apgar values: 40 babies from the entire sample (5.8%) had low Apgar in the first minute, and 8 (1%) in the fifth minute. The Apgar at the first minute obtained an overall mean of 8 points (SD 1), and 9 points (SD 0.7) at 5 minutes. Table 2 presents the characteristics of the newborns according to gestational weight gain. The numbers and percentages of newborns were as follows: 21 (3%) were SGA; 543 (79.6%) AGA; 119 (17.4%) LGA; 49 (7.2%) were MCR; and 35 (5.1%) of the newborns required hospitalization in an intensive care unit. The number of infants at birth, according to their aforementioned classification, was related to the gestational weight gain, identifying a significant value for the birth of AIG, LGA and macrosomic (MCR) NB's (P < 0.01). There was, however, no significant relationship for SGA infants (P = 0.77). The comparison of the gestational age at delivery was similar and not expressive for the three groups, i.e., it did not show a significant difference (P > 0.05), with an overall mean of 38.5 weeks.
The comparative result between the number of preterm births and the weight gain of pregnant mothers was not significant. However, the classification of infants at birth showed differences in the groups in comparison and found a higher average weight (3,486 g) for newborns of mothers who had above-adequate weight gain. The number of cesarean deliveries (NCD) and low birth weight (LBW) were not statistically significant (P > 0.05). Similarly, for Apgar at the 1 st and 5 th minutes (P = 0.74) and (P = 0.10) respectively, not confirming an association for values lower than seven. Table 3 shows the odds ratios relating pregnant women with weight gain below and above the recommended level compared to pregnant women with adequate weight gain, the type of treatment used by pregnant women, and the weight classification of newborns. The results were as follows: the three groups of pregnant women in the study did not have different treatment needs in all the therapeutic methods used in the research, and the therapy did not interfere in the weight gain of pregnant mothers.
As for the number of infants at birth, according to the Battaglia and Lubchenco classification 12 , and for the MCR infants (considered neonates weighing more than 4,000 g), there were no differences in the gestational groups regarding the birth of SGA and MCR NB, according to the comparative proposal in Table 3 . On the other hand, in the women who presented above-adequate weight gain, the study showed a decreased alteration for AGA newborns (OR = 0.50; 95% CI 0.28-0.91) and increased for LGA newborns (OR = 1.9, 95% CI 1.01-3.5). ...continuation - Table 1 Association between gestational weight gain, birth weight classification, and type of treatment in diabetic mothers 
DISCUSSION
This study aimed to identify the relationship between weight gain with the use of treatments in diabetic pregnant women and, consecutively, with the possible outcomes corresponding to the number of newborns according to the classification of their weight. Table 1 shows that, statistically, gestational age at the time of diagnosis and pre-gestational BMI were significant for weight gain in diabetic mothers. However, between the two variables, pre-gestational BMI was more compatible with the literature regarding this relationship, with pre-gestational BMI being a relevant variable relative to the odds of acquiring weight during Association between gestational weight gain, birth weight classification, and type of treatment in diabetic mothers gestation 13 . Regarding the differences in treatments for diabetic pregnant women, it was noticed that the literature presents results and/or a contraposition to our goals. The literature consulted indicates a significant association between the treatments and the possible parameters regarding the weight gain of the mothers. In treatments with metformin, authors have identified a reduction in the weight of diabetic pregnant women 14, 15 . Similarly, Ashoush et al. 16 who used the "metformin plus insulin" treatment found evidence of differences in the weight of the pregnant women in the results obtained.
However, other researchers have identified the relationship between weight gain in pregnancy and the need for different treatments, as in studies by Sun et al. 17 , in which gestational weight gain personalized the dietary program for diabetic pregnant women, contradicting our results which did not show differences in the "diet" and "metformin plus insulin" treatments in the three selected groups. However, it was evident that in the "insulin" and "metformin" treatments the probability of there being a difference between the groups relating to gestational weight gain and to different therapies was significant.
Controlling blood glucose is essential to avoid unfavorable outcomes. However, the choice of medication is essential to prevent harmful results for both mother and newborn 5, 7, 8 . Thus, it is emphasized that after the hypoglycemic therapies were administered to the pregnant women, differences were identified regarding fasting blood glucose levels and non-significant value was found for postprandial blood glucose levels. The relationship between blood glucose levels and gestational weight gain is still recent and reduced in the literature. Table 2 shows the characteristics of the NB according to the gestational weight gain in diabetic mothers. The study did not present relation to SGA newborns and identified differences for AIG, LGA, and MCR newborns. However, studies by Corrêa et al. 18 identified only the relationship between diabetic mothers and MCR newborns, independent of weight gain.
It has become noticeable in scientific research to attribute preterm births to maternal glucose levels and to mothers with diabetes preceding pregnancy 19 . In our research, it was not possible to point to evidence for the association of premature births with weight gain in diabetic pregnant women 20 . According to the literature, there is an apparent correlation between diabetic pregnant women who present weight gain above the appropriate standard and an increase in the percentage of cesarean deliveries 21 . However, in our results, it was not possible to confirm this statement. In the same way, the comparison of the low birth weight (LBW) NB did not present any significant relationship with the weight gain of the diabetic pregnant woman.
The verification of characteristics comparing the weight gain of the mother with lower Apgar scores in the 1 st and 5 th min. did not denote significant differences for Apgar scores less than seven. Other authors who have studied pregnant women with GDM and their respective neonatal outcomes similarly identified non-significant Apgar values in an equivalent comparison 21 . Table 3 presents the results regarding the needs of diverse treatments according to the comparative proposal of the study. In this context, there was no identification of odds for differentiated treatments in all therapies applied when correlating them with the classification corresponding to the weight gain of pregnant women.
Regarding the relation between the weight of the newborn and the weight gain in diabetic pregnant women, the literature consulted confirms the possibility of the birth of MCR babies in mothers with above-adequate weight and, concomitantly, that a mother with GDM who experiences above-adequate weight gain is at risk of bearing a LGA NB 22 . These results were similar in our retrospective observational research. However, in our comparisons, the mean BMI corresponding to the total number of pregnant women was relatively high (29 kg/ m²).
Thus, the mean weight of the sample may have influenced the results obtained, that is, pregnant women who gained weight below the adequate index did not show an odds ratio for a greater number of SGA children, raising a divergent hypothesis in comparison with other studies which, in turn, presented significant odds of below-weight diabetic mothers generating SGA newborns 23 . In the results of this study, in identifying that pregnant women with below-adequate weight gain were not at increased odds of having SGA infants, it was suggested that a more restricted diet could be used in a more comfortable condition, without the possibility of unfavorable outcomes for both mother and to the NB.
There is a scientific interest in unveiling the fundamental etiological factors that interfere with pregnant weight gain and possible neonatal outcomes [22] [23] [24] . Thus, the large number of patients and the lack of similar studies have made the results and conclusions of this research qualified and/or relevant. However, studies with larger casuistics may strengthen these conclusions, renewing or converging to the possibilities of precautions for pregnant women with above-expected weight gains, while simultaneously attenuating concerns for pregnant women with weight gain below normal.
It is undeniable that guiding our diabetic pregnant women to control their diet during pregnancy may prevent deleterious perinatal outcomes. However, concern for the diets of diabetic pregnant women are already evident in scientific researches aimed at controlling blood glucose levels.
However, it does not exempt the need to describe a diet whose target is an adequate and individualized weight gain for each patient, considering the possible variables corresponding to their pre-gestational BMI and being sufficiently compatible to supply the physiological needs for appropriate development of the child. In this context, consultations with nutritionists and/or professionals with experience in the area, would be relevant and preventive in relation to the complications of weight gain in pregnant women with GDM. The present study presented some limitations, such as the small number of studies using metformin for discussion. Another restrictive factor was the limited follow-up of infants in infancy whose pregnant mothers were administered different drugs.
Therefore, we could have a better parameter on the use of oral and/or hypoglycemic antidiabetics. Another obstacle was the nonuse of the double blind in several clinical trial studies to avoid the placebo effect in the use of different drugs. The strong point was the number of studies with obese pregnant women, which enabled us to perform better comparative analyses of our objectives.
CONCLUSION
In the comparison of pregnant mothers who experienced below-and aboveadequate weight gain with pregnant women who experienced adequate weight gain, the following results were presented: the present study found no difference in the therapy used in pregnant women who gained below or above the recommended amount of weight in comparison with those who gained an adequate amount of weight.
Regarding the results related to the weight of the baby at birth, below-adequate weight gain in the mothers was not shown to be significant in relation to the weight classification of the newborns. However, mothers with aboveadequate weight gain presented higher odds of bearing children considered large for their gestational age and thus were less likely to have children with adequate weight for their gestational age. 
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diminuiu a chance de ter um filho adequado para a idade gestacional em 50% e dobrou a de ter um filho grande para a idade gestacional. Comparando os grupos, conforme o ganho de peso através da razão de chance, não foi encontrada diferença na terapêutica utilizada.
Palavras-chave: Diabetes gestacional. Ganho de peso. Índice glicêmico. Peso ao Nascer.
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Associação entre ganho de peso gestacional, classificação de peso ao nascer e tipo de tratamento em mães diabéticas
O diabetes mellitus gestacional (DMG) é definido como uma intolerância à glicose que se inicia ou é detectada pela primeira vez durante a gestação. Como outras formas de hiperglicemia, o DMG é caracterizado pela insuficiência das células beta-pancreáticas ao suprir a demanda corporal de insulina. De acordo com os critérios da nova International Association of the Diabetes and Pregnancy Study Group foi desenvolvido um estudo de coorte multinacional heterogêneo com uma amostra de mães gestantes de diversas raças no período gestacional entre 24-32 semanas. Neste estudo a Hiperglicemia e Adversa Resultado da Gravidez apresentou, no geral, 55% das gestantes com glicemia em jejum (GJ) no limite para DMG, o resultado 1-H era o valor diagnóstico em 33%, e o valor de 2 h o valor diagnóstico foi de 12%
1 . Um diagnóstico de DMG é sempre compatível com um tratamento clínico, frequentemente originando-se com adequados procedimentos alimentares e programas de atividades físicas. Contudo, se essas medidas não forem satisfatórias, inicia-se um tratamento farmacológico em concomitância com um programa alimentar. Quanto ao tratamento dietético, o mesmo deve ser fundamentado em um programa alimentar que possibilite de maneira sincrônica um ganho de peso adequado e um congruente controle metabólico 2 . Entretanto, se após o período de duas semanas de tratamento os níveis glicêmicos continuarem alterados o uso de medicamentos farmacológicos deve ser iniciado 3 . A escolha terapêutica no DMG é de grande importância para as pesquisas científicas, principalmente devido às complicações e intercorrências perinatais, assim como as variáveis que podem interferir nas dosagens e/ou tipo de tratamentos. A bibliografia revela que de modo geral o tratamento para o DMG preconiza a insulina como o principal medicamento a administrar. Contudo, é de fundamental importância a conformidade referente aos ajustes e/ou associações com a insulina humana, bem como os benefícios de sua ação rápida e intermediária, visto que o ajuste da dose deve ser individualizado para cada paciente 4 . Todavia, verifica-se em estudo recente a possibilidade do uso de antihiperglicemiantes orais, sendo uma opção gradativamente mais aceita nos desfechos do DMG 5 . Em contrapartida, vale destacar estudos na década de 90 que contraindicavam o uso de antihiperglicemiantes orais na gestação, devido a relatos de casos e estudos com pequenas amostras, que sugeriram efeitos adversos sobre o desenvolvimento do feto 6 . O ganho de peso ideal durante a gestação apresentou medidas alternadas na literatura 7 . Cientificamente, o ganho de peso deve variar conforme o índice de massa corporal (IMC) pré-gestacional, tanto para as diabéticas quanto para as pacientes sem comorbidades.
Na década de 2000, um estudo com gestantes sem DMG concluíu uma relação entre o ganho de peso excessivo durante a gestação com desfechos de fetos macrossômicos e maior necessidade de partos cesarianos. Em equivalência oposta, o estudo revelou que as gestantes que adquiriram um ganho de peso inadequadamente baixo geraram fetos com baixo peso ao nascer e maior número de partos prematuros 8 . Desta forma, o objetivo deste estudo é identificar a relação entre o ganho de peso gestacional e os desfechos no DMG, tipo de tratamento utilizado e peso do bebê ao nascer. Classificamos o ganho de peso conforme recomendações do Institute of Medicine, 2009 (IOM), que considera o IMC pré-gestacional, do seguinte modo: para gestantes com baixo peso, o ganho recomendado é de 13 a 18 kg; para gestantes com peso normal, o ganho recomendado é de 11 a 16 kg; para gestantes com sobrepeso, o ganho recomendado é de 7 a 11 kg; para gestantes obesas, o ganho recomendado é de 5 a 9 kg. Logo, um ganho de peso insuficiente foi classificado como "abaixo do adequado" e um ganho de peso alto foi classificado como 'acima do adequado 11 . Os dados coletados foram: idade, idade gestacional do diagnóstico de DMG; IMC pré-gestacional, ganho de peso gestacional, número de gestações, glicemia de jejum, glicemia pós prandial, prescrição de dieta, uso de metformina, uso de insulina, tipo de parto, apgar no primeiro e quinto minuto, idade gestacional do parto (verificada através da data da última menstruação e ultrassom precoce), peso do bebê ao nascimento, número de crianças prematuras (com menos de 37 semanas), número de crianças classificadas como pequenos para a idade gestacional (PIG), que são aqueles abaixo do percentil 10, adequado para a idade gestacional (AIG), que são aqueles entre o percentil 10 e o percentil 90 e grande para a idade gestacional (GIG), que são aqueles acima do percentil 90 12 , e considerou-se macrossômicos, neonatos com peso maior que 4.000 g .
MÉTODOS
Os dados foram armazenados no programa excell 2010, com o uso do programa SPSS 21 para análise estatística. As variáveis nominais foram analisadas em números absolutos e percentagens, as contínuas em médias e desvios padrões. Utilizou-se o teste Q² exato de Fisher para análise das proporções, Kruskall Wallis para amostras independentes de acordo com os três grupos selecionados, conforme o ganho de peso gestacional, o teste T de Student para comparações das médias entre os grupos selecionados foi utilizado apenas para as características maternas e tipo de tratamento de acordo com ganho de peso gestacional. Construídos modelos de regressão logística multivariada multinomial (variáveis categóricas) e consecutivamente cálculo de razão de chance, de modo a verificar se o ganho de peso da gestante diabética interfere no tratamento utilizado e no peso do bebê ao nascer. Para estas comparações vale destacar que os grupos de gestantes diabéticas com ganho de peso abaixo e acima do adequado foram comparadas com as gestantes com o ganho de peso adequado. As variáveis de confusão foram: idade materna, idade gestacional do diagnóstico, IMC pré-gestacional e tipos de tratamentos. Intervalos de confiança de 95% (IC95%) foram estabelecidos, sendo que serão considerados valores significativos quando p<0,05. abaixo do adequado quanto acima.
Medidas terapêuticas foram propostas para todas as gestantes da seguinte forma: a terapêutica com dieta foi utilizada para 282 (41,3%) gestantes, as quais não necessitaram terapêutica complementar, o tratamento com insulinoterapia para 102 (14,9%), a metformina foi necessária em 242 (35.4%), e por último a combinação metformina com insulina para 56 (8,2%) das gestantes do estudo.
A utilização das terapias: "dieta" e "metformina mais insulina", não demonstrou diferenças entre os três grupos selecionados, apontando valor não significativo (P>0,05). Contudo, os tratamentos com "insulinoterapia" e "metformina", aplicados separadamente, apontaram resultados significativos com p= 0,00 (p<0,01) para os dois tipos de intervenção de acordo com as categorizações relacionadas ao ganho de peso gestacional.
Após as medidas terapêuticas, a glicemia de jejum foi de 89.4 mg/dl (DP 12 mg/dl) e a glicemia pós prandial, de 117 mg/dl (DP 17.5 mg/dl) nas gestantes de peso adequado. Nos três grupos selecionados a análise comparando os níveis glicêmicos com os respectivos tratamentos administrados apresentou significância na glicemia em jejum (p<0,01) e consecutivamente não houve significância estatística quanto à glicemia pós-prandial (p=0,26).
No presente estudo, a via de parto mais comum foi cesariana, com 52,5% (358) das crianças nascidas por esse meio; 7,1% (49) dos recém-nascidos foram prematuros. Quanto aos valores de apgar: os bebês de toda a amostra 40 (5.8%) tiveram apgar baixo no primeiro minuto e 8 (1%) no quinto minuto. O apgar ao primeiro minuto obteve uma média geral de 8 desvio padrão (DP 1) e ao quinto minuto de 9 pontos (DP 0.7).
A tabela 2 apresenta as características dos bebês ao nascer de acordo com o ganho de peso gestacional. Os números e percentuais de bebês ao nascer apresentaram-se da seguinte forma: 21 (3%) eram RN PIG, 543 (79,6%) RN AIG, 119 (17,4%) RN GIG, 49 (7.2%) eram RN (MCR) e 35 (5.1%) de recém-natos necessitaram de internação em unidade de tratamento intensivo. O número de bebês ao nascimento, de acordo com a sua classificação supracitada, foi relacionado ao ganho de peso gestacional, identificando valor significativo para o nascimento de RN AIG, GIG e macrossômicos (MCR) (p<0,01). Não houve, entretanto, relação significativa para os recém-nascidos PIG (p=0,77). A comparação correspondente à idade gestacional do parto foi semelhante e não expressiva para os três grupos, ou seja, não demonstrou significância (P>0,05), identificando uma média geral de 38.5 semanas.
O resultado comparativo entre o número de partos prematuros com o ganho de peso das mães gestantes não foi significante. Todavia, a classificação dos bebês ao nascimento apontou diferenças nos grupos em comparação e constatou maior peso médio 3.486 g para os neonatos de mães acima do peso adequado. O número de partos cesarianos (NPC) e o baixo peso ao nascer (BPN) não apresentaram significância estatística (P>0,05). Da mesma forma, quanto ao Apgar no 1º e 5º minuto (p=0,74) e (p=0,10) respectivamente, não confirmando uma associação para valores menor que sete.
A tabela 3 demonstra a razão de chances relacionando as gestantes com ganho de peso abaixo e acima do recomendado em comparação com as gestantes com ganho de peso adequado, do tipo de tratamento utilizado pelas gestantes e da classificação de peso dos recém-nascidos. Os resultados ocorreram da seguinte forma: na comparação entre os grupos de gestantes já supramencionados, as mesmas não tiveram necessidades de tratamentos diferenciados em todos os métodos terapêuticos utilizados na pesquisa e a terapêutica não interferiu no ganho de peso das mães gestantes.
Quanto ao número de bebês ao nascimento, de acordo com a classificação de Battaglia e Lubchenco 12 e para os RN MCR, que se consideraram os neonatos com peso maior que 4.000 g, não houve diferenças nos grupos gestacionais quanto ao nascimento de RN PIG e MCR, conforme proposta comparativa da tabela 3. Em contrapartida, nas gestantes com peso acima do adequado, o estudo apontou uma alteração diminuída para os recém-nascidos AIG (OR=0.50; IC95% 0.28-0.91) e aumentada para os recém-nascidos GIG (OR=1.9; IC95% 1.01-3.5). 
DISCUSSÃO
Este estudo buscou identificar a relação entre o ganho de peso com a utilização de tratamentos em gestantes diabéticas e, consecutivamente, com os possíveis desfechos correspondentes ao número de recém-nascidos de acordo com a classificação de seu peso.
Na tabela 1 dentre os resultados encontrados, observou-se que, estatisticamente, a idade gestacional no momento do diagnóstico e o IMC pré-gestacional mostraram-se significantes quanto ao ganho de peso das mães diabéticas. No entanto, entre as duas variáveis verificadas, o IMC pré-gestacional foi mais compatível com a literatura quanto a esta relação, sendo o IMC pré-gestacional uma variável relevante quanto às chances de adquirir peso durante a gestação 13 . Quanto às diferenças nos tratamentos para gestantes diabéticas, percebeu-se que a literatura apresenta resultados e/ou uma contraposição às nossas metas. A bibliografia consultada aponta uma associação significativa entre os tratamentos e os possíveis parâmetros quanto ao ganho de peso das mães. Nos tratamentos com metformina, autores identificaram uma redução no peso das gestantes diabéticas 14, 15 . Da mesma forma, Ashoush et al 16 que fizeram uso da terapêutica "metformina mais insulina" evidenciando diferenças quanto ao peso das gestantes nos resultados obtidos.
No entanto, outros pesquisadores identificaram a relação ganho de peso na gestação com a necessidade de diferentes tratamentos, como nos estudos de Sun et al 17 , em que o ganho de peso gestacional personalizou o programa de dietas para gestantes diabéticas, fazendo contradição aos nossos resultados que não demonstraram diferenças nos tratamentos com "dieta" e na terapêutica com "metformina mais insulina", nos três grupos selecionados. Contudo, ficou evidente que nos tratamentos com "insulina" e nas terapias com "metformina" a probabilidade de haver diferença entre os grupos relacionando ganho de peso gestacional e distintas terapêuticas foi significativa. O controle glicêmico é fundamental para evitar desfechos desfavoráveis. No entanto, a escolha do medicamento tornase imprescindível para prevenir resultados deletérios tanto para mãe quanto para RN. 5, 7, 8 Dessa forma, ressalta-se que após as terapias hipoglicêmicas administradas pelas gestantes, identificaram-se diferenças quanto a glicêmica de jejum e valor não significativo para glicemia pós-prandial. A relação entre níveis glicêmicos e ganho de peso gestacional ainda é recente e reduzida na literatura.
A tabela 2 evidencia as características do RN de acordo com o ganho de peso gestacional em mães diabéticas. O estudo não apresentou relação para RN PIG e identificou diferenças para RN AIG, GIG e MCR. Contudo, os estudos de Corrêa et al 18 identificaram somente a relação de mães diabéticas com bebês MCR, independente do ganho de peso.
Sobre partos prematuros, tomou-se perceptível nas pesquisas científicas o direcionamento de suas causas para os níveis maternos de glicose e para as mães com diabetes precedente à gestação 19 . Em nossa pesquisa, não foi possível evidenciar a associação de partos prematuros com o ganho de peso em gestantes diabéticas 20 . De acordo com a literatura, são aparentes as afirmativas correlacionando as gestantes diabéticas com ganho de peso acima do padrão adequado com um aumento no percentual de partos cesarianos 21 . No entanto, em nossos resultados, não foi possível realizar esta afirmativa. Da mesma forma, na comparativa correspondente aos RN de baixo peso ao nascer (BPN), não apresentando significância na relação com o ganho de peso da gestante diabética.
A verificação das características confrontando o ganho de peso da mãe com valores inferiores para o apgar no 1º e 5º min. não denotou diferenças significativas para valores menores que sete. Bem como outros autores, que estudaram gestantes com DMG com respectivos desfechos neonatais, identificaram valores de apgar não considerável em uma comparação equivalente 21 . A tabela 3 apresenta os resultados referentes às necessidades de tratamentos diversificados de acordo com a proposta comparativa do estudo. Neste contexto, não houve identificação de chances para tratamentos diferenciados em todas as terapias aplicadas quando ao relacioná-las com a classificação correspondente ao ganho de peso das gestantes.
Quanto à relação correspondente ao peso do RN com o ganho de peso em gestantes diabéticas, a bibliografia consultada confirma a possibilidade de nascerem bebês MCR em mães com peso acima do adequado e concomitantemente uma mãe com DMG que adquiriu ganho de peso acima do preconizado apresenta riscos de gerar um RN GIG. 22 . Estes resultados foram semelhantes em nossa pesquisa retrospectiva observacional. No entanto, em nossas comparações, a média de IMC correspondente ao número total de gestantes foi relativamente elevada (29 kg/m²).
Desta forma, a média de peso da amostra pode ter influenciado nos resultados obtidos, ou seja, as gestantes que ganharam peso abaixo do índice adequado não demonstraram razão de chances para um maior número de crianças PIG, levantando uma hipótese divergente em comparação com outros estudos científicos, que por sua vez, apresentaram chances significativas de mães diabéticas de baixo peso gerarem RN PIG 23 . Nos resultados conferidos neste estudo, ao identificar que as gestantes de baixo peso não aumentaram as chances para RN PIG, sugere-se que uma dieta mais restrita poderia ser utilizada em uma condição mais confortável, sem a possibilidade de desfechos desfavoráveis tanto para mãe quanto para aos RN.
Existe um interesse científico em desvendar os fatores etiológicos fundamentais que interferem no ganho de peso da gestante e nos possíveis desfechos neonatais [22] [23] [24] . Desta forma, o grande número de pacientes e a falta de estudos semelhantes, tornaram qualificados e/ ou relevantes os resultados e conclusões desta pesquisa. Entretanto, estudos com maiores casuísticas poderão fortalecer estas conclusões, renovando ou convergindo às possibilidades de precauções para com as gestantes com o ganho de peso acima do esperado, e simultaneamente atenuando as preocupações com as gestantes com ganho de peso abaixo do padrão de normalidade.
É incontestável que orientar nossas gestantes diabéticas a controlar sua dieta durante a gestação poderá prevenir desfechos perinatais deletérios. Todavia, já são evidentes nas pesquisas científicas as preocupações com as dietas para gestantes diabéticas objetivando o controle dos níveis glicêmicos. Entretanto, não exime a necessidade de descrever uma dieta visando um ganho de peso adequado e individualizado para cada paciente, tendo em vista as possíveis variáveis correspondentes ao seu IMC pré-gestacional e sendo suficientemente compatível para suprir as necessidades fisiológicas para o desenvolvimento apropriado da criança. Nesse contexto, as consultas com nutricionistas e/ou profissionais com experiência na área, seriam de caráter relevante e preventivo em relação às intercorrências sobre o ganho de peso em gestantes com DMG.
O presente estudo apresentou algumas limitações, como o reduzido número de
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Associação entre ganho de peso gestacional, classificação de peso ao nascer e tipo de tratamento em mães diabéticas CONCLUSÃO Na comparativa das mães grávidas com peso abaixo e acima do adequado com as gestantes de peso adequado, apresentaram os seguintes resultados: o presente estudo não encontrou diferença na terapêutica utilizada nas gestantes que ganharam peso abaixo ou acima do recomendado em comparação com aquelas que tiveram ganho de peso adequado.
Quanto 
